CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

Author's Avatar
Feb 21, 2023

The trial did not meet its primary endpoint, however, the totality of data supports Barostim’s use as an effective treatment for patients with heart failure